Press-release for stocks related to cel

Prices are updated after-hours

tags : Cel crawled time : 01:00

save search

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Published: 2022-03-02 (Crawled : 01:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M

Health Technology

| -87.67% | O: -28.03% H: 1.74% C: -16.2%
xpovio treatment approval cel t-cell

Giving Hits New High as RE/MAX Celebrates 30 Years of Partnership with Children's Miracle Network Hospitals
Published: 2022-03-01 (Crawled : 01:00) - prnewswire.com
RMAX | $7.25 1.54% 0.0% 220K

Finance

| -75.72% | O: 0.52% H: 0.0% C: 0.0%
partnership als cel work children

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
Published: 2022-03-01 (Crawled : 01:00) - prnewswire.com
CTIC | $9.09 0.05% 11M

Health Technology

| 295.43% | O: 22.61% H: 0.0% C: 0.0%
treatment fda biopharma fibrosis approval cel

Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
Published: 2022-02-21 (Crawled : 01:00) - prnewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| Email alert Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| Email alert Add to watchlist
ibi345 car-t cel t-cell

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 213.47% | O: -2.3% H: 1.23% C: 0.29%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -21.29% | O: -0.94% H: 0.21% C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 213.47% | O: -2.3% H: 1.23% C: 0.29%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -21.29% | O: -0.94% H: 0.21% C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation

Sutherland Wins 2021 Brandon Hall Group HCM Excellence Awards in Four Categories: Reinventing Learning with Cognitive Technologies
Published: 2022-02-03 (Crawled : 01:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -15.81% | O: -0.65% H: 0.0% C: 0.0%
awards cel group

Celestica Announces Fourth Quarter 2021 Financial Results
Published: 2022-01-26 (Crawled : 01:00) - globenewswire.com
PAYD | News | $1.61 -25.0% 100

Information

| -36.51% | O: -0.79% H: 0.0% C: 0.0%
CLS | $40.73 -7.03% -0.66% 4.5M

Electronic Technology

| 316.68% | O: 3.37% H: 9.44% C: 2.65%
CSCO | $48.33 0.46% 0.46% 20M

Technology Services

| -12.81% | O: 0.33% H: 1.84% C: -1.6%
financial results cel

Amedisys Honors 37 Employees with Annual Spirit of Excellence Award
Published: 2022-01-26 (Crawled : 01:00) - globenewswire.com
AMED | $90.38 -0.44% -0.44% 380K

Health Services

| -29.23% | O: 0.71% H: 0.0% C: -3.9%
cel awards

CBNK Accelerating Loan Growth Drives Steady Profits and Returns
Published: 2022-01-26 (Crawled : 01:00) - globenewswire.com
CBNK | $19.575 1.95% 1.92% 23K

Finance

| -23.35% | O: 0.4% H: 2.85% C: 0.63%
cel growth

Venus Concept Receives FDA 510(k) Clearance of Venus BlissMAX for Non-Invasive Lipolysis of the Abdomen and Flanks, Cellulite Reduction and Muscle Conditioning
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
VERO | $0.85 1.19% 1.18% 15K

Health Technology

| -57.22% | O: -0.56% H: 0.0% C: 0.0%
fda clearance cel

NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
NEXI | $3.22 -2.42% -2.48% 23K

| -15.09% | O: -4.85% H: 0.0% C: 0.0%
program leukemia cel therapy

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 53.89% | O: -0.37% H: 0.0% C: 0.0%
keytruda cel

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
Published: 2022-01-19 (Crawled : 01:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -53.25% | O: -1.32% H: 1.57% C: -0.21%
stone-302 treatment ema ces cel lung cancer cancer

Motorsport Games Celebrates One Year Anniversary of IPO, Rings NASDAQ Closing Bell
Published: 2022-01-12 (Crawled : 01:00) - globenewswire.com
MSGM | $2.63 5.62% 5.32% 14K

| -43.3% | O: -3.35% H: 7.67% C: 3.96%
games cel nasdaq

Celestica Announces Date for Fourth Quarter 2021 Financial Results
Published: 2022-01-12 (Crawled : 01:00) - globenewswire.com
CLS | $40.73 -7.03% -0.66% 4.5M

Electronic Technology

| 299.21% | O: 0.61% H: 2.99% C: 0.52%
financial results ces cel results

Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease
Published: 2021-12-30 (Crawled : 01:00) - globenewswire.com
MESO | $5.19 1.57% 1.54% 230K

Health Technology

| 6.24% | O: 0.0% H: 2.3% C: -0.21%
fda disease cel children

629AB, Associate Director / Principal Scientist, Flow Cytometry Cell Therapy Analytics
Published: 2021-12-24 (Crawled : 01:00) - fatetherapeutics.com
FATE | $4.795 -4.86% -5.11% 2.7M

Health Technology

| Email alert Add to watchlist
analytics cel therapy

BioSig Technologies, Inc. Selects Access Strategy Partners to Accelerate Commercial Sales
Published: 2021-12-21 (Crawled : 01:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -13.59% | O: 0.18% H: 0.02% C: -0.51%
BSX | $67.33 -0.13% -0.31% 7M

Health Technology

| 70.68% | O: 1.19% H: 2.95% C: 2.85%
BSGM | $1.41 -8.44% -9.22% 200K

Health Technology

| -42.59% | O: 0.0% H: 0.0% C: -9.89%
sales cel commercialization

Five Below Celebrates Another Successful Year of Giving as 2021 Draws to a Close
Published: 2021-12-21 (Crawled : 01:00) - globenewswire.com
FIVE | $150.25 -1.15% -1.16% 870K

Retail Trade

| -15.77% | O: 1.15% H: 2.38% C: 2.13%
cel